Clinical Utility of Radiologic Disease Reassessment in the Management of Pediatric B-Cell Non-Hodgkin Lymphoma.
Adolescent
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Child
Child, Preschool
Disease Management
Female
Humans
Infant
Lymphoma, B-Cell
/ diagnostic imaging
Magnetic Resonance Imaging
Male
Neoplasm, Residual
/ diagnostic imaging
Prognosis
Retrospective Studies
Tomography, X-Ray Computed
Ultrasonography
Journal
Journal of pediatric hematology/oncology
ISSN: 1536-3678
Titre abrégé: J Pediatr Hematol Oncol
Pays: United States
ID NLM: 9505928
Informations de publication
Date de publication:
01 04 2021
01 04 2021
Historique:
received:
29
10
2019
accepted:
16
02
2020
pubmed:
29
3
2020
medline:
20
5
2021
entrez:
29
3
2020
Statut:
ppublish
Résumé
Although outcomes for children with B-cell non-Hodgkin lymphoma are excellent, between 20% and 40% demonstrate residual radiologic abnormalities at disease assessment during consolidation therapy, the significance of which remains uncertain. The authors report the outcomes for all children treated for B-cell non-Hodgkin lymphoma at our center over an 11-year period. Twenty-four of 64 (38%) children had residual radiologic abnormalities at disease remission assessment. Seven (29%) underwent histologic biopsies that were normal. No children with residual radiologic abnormalities experienced disease relapse or death, suggesting that imaging at this time point creates clinical uncertainty without indicating residual disease or predicting relapse.
Identifiants
pubmed: 32218099
pii: 00043426-202104000-00024
doi: 10.1097/MPH.0000000000001781
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e380-e384Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Li J, Thompson TD, Miller JW, et al. Cancer incidence among children and adolescents in the United States 2001-2003. Pediatrics. 2008;121:1470–1477.
Ehrhardt MJ, Sandlund JT, Zhang N, et al. Late outcomes of adult survivors of childhood non-Hodgkin lymphoma: a report from the St. Jude Lifetime Cohort Study. Pediatr Blood Cancer. 2017;64:6.
Minard-Colin V, Brugieres L, Reiter A, et al. Non-Hodgkin lymphoma in children and adolescents: progress through effective collaboration, current knowledge, and challenges ahead. J Clin Oncol. 2015;33:2963–2974.
Bailly C, Eugene T, Couec ML, et al. Prognostic value and clinical impact of FDG-PET in the management of children with Burkitt lymphoma after induction chemotherapy. Front Med. 2014;54:1–5.
Karmazyn B, Ash S, Goshen Y, et al. Significance of residual abdominal masses in children with abdominal Burkitt’s lymphoma. Paediatr Radiol. 2001;31:801–805.
Burkhardt B, Reiter A, Landmann E, et al. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group. J Clin Oncol. 2009;27:3363–3369.
Bluhm EC, Ronckers C, Hayashi RJ, et al. Cause-specific mortality and second cancer incidence after non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood. 2008;111:4014–4021.
Sandlund JT. Burkitt lymphoma: staging and response evaluation. Br J Haematol. 2012;156:761–765.
Sandlund J, Guillerman P, Perkins S, et al. International pediatric non-Hodgkin lymphoma response criteria. J Clin Oncol. 2015;33:2106–2110.
Surbone A, Longo DL, De Vita VT, et al. Residual abdominal masses in aggressive non-Hodgkins lymphoma after combination chemotherapy: significance and management. J Clin Oncol. 1988;6:1832–1837.
Bhojwani D, McCarville M, Choi J, et al. The role of FDG-PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphoma. Br J Haematol. 2015;168:845–853.
Eissa HM, Allen CE, Kamdar K, et al. Pediatric Burkitt’s lymphoma and diffuse B-cell lymphoma: are surveillance scans required? Paediatr Haematol Oncol. 2013;31:253–257.
Leung W, Sandlund JT, Hudson MM, et al. Second malignancy after treatment of childhood non-Hodgkin lymphoma. Cancer. 2001;92:1959–1966.
Rahman HA, Sedky M, Hamada A, et al. Role of FDG-PET scan in the management of paediatric mature B cell non-Hodgkin’s lymphoma. CCHE experience. J Egypt Natl Cancer Inst. 2016;28:95–99.
Berger-Achituv S, Bella B, Hanna G, et al. The role of 18F-FDG-PET/CT for early response evaluation in pediatric high-grade B-cell lymphoma patients treated with the Inter-B-NHL Ritux 2010 protocol. Br J Haematol. 2018;182(suppl 1):108; abstract.